These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 14663635)
1. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Terauchi F; Hirano T; Taoka H; Masaki K; Yamamoto Y; Ogura H; Kubo H Int J Clin Oncol; 2003 Dec; 8(6):348-51. PubMed ID: 14663635 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145 [TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688 [TBL] [Abstract][Full Text] [Related]
5. Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study. Briasoulis E; Pentheroudakis G; Timotheadou H; Rammou D; Pavlidis N; Fountzilas G Anticancer Drugs; 2004 Sep; 15(8):747-52. PubMed ID: 15494635 [TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Tinker AV; Gebski V; Fitzharris B; Buck M; Stuart-Harris R; Beale P; Goldrick A; Rischin D Gynecol Oncol; 2007 Mar; 104(3):647-53. PubMed ID: 17079006 [TBL] [Abstract][Full Text] [Related]
11. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231 [TBL] [Abstract][Full Text] [Related]
12. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Koukourakis MI; Bizakis JG; Skoulakis CE; Kyrmizakis D; Giatromanolaki A; Papadakis CE; Prokopakis E; Amanakis Z; Hellidonis ES Anticancer Res; 1999; 19(3B):2305-9. PubMed ID: 10472349 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585 [TBL] [Abstract][Full Text] [Related]